Alaproclate: a pharmacokinetic and biochemical study in patients with dementia of Alzheimer type.
Alaproclate, a specific inhibitor of neuronal serotonin re-uptake, was given to 12 patients with dementia of Alzheimer type. The drug was rapidly absorbed and an elimination half-life of 7.1 +/- 0.9 h (+/- SD, n = 8) was calculated. Plasma protein binding for alaproclate was 82 +/- 1%. Two weeks of repeated administration produced plasma concentrations of alaproclate similar to those predicted from a single dose. The pharmacological effect of the drug was demonstrated by an inhibition of serotonin uptake in the patients' platelets and a reduction of the serotonin concentration in blood. Global rating of clinical efficacy showed a positive effect of alaproclate in five of the patients, mainly regarding emotional functions.
D000368:Aged; D000409:Alanine / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D000544:Alzheimer Disease / Q000097:blood / Q000188:drug therapy*; D003704:Dementia / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D012701:Serotonin / Q000097:blood
D012701:Serotonin; C025293:alaproclate; D000409:Alanine